Skip to main content

John R. La Montagne Memorial Symposium on Pandemic Influenza Research Meeting Proceedings (2005) / Chapter Skim
Currently Skimming:

5 Afternoon Discussion: Reaction to Rapporteurs, Day 1
Pages 99-102

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 99...
... And that might really throw things out of kilter. PARTICIPANT: I was also in Group 1, another point that I would make is that I think we all agreed on is that any sequencing data and attempts to correlate sequence with virulence need to be accompanied by very careful and detailed clinical histories of the individuals from whom these samples were obtained.
Read the entire page →
From page 100...
... The answer has tremendous implications for how we deal with it, because one is probably more of a secondary bacterial pneumonia type picture and the other not. I think that this area needs a lot more research because we have artificially lumped all pandemics under one category, when in fact they may be of a common origin, but not of common outcome or cause.
Read the entire page →
From page 101...
... Economically, this can be very cost effective to do this, because instead of having to go to complicated and very costly and dangerous clinical trials, it means that you could develop at least attenuated strains of contemporary viruses to have those available. I say this with feeling, because I have recently been through an experience with a clinical trial where an up-todate strain was not available.
Read the entire page →
From page 102...
... There are other possible approaches that presumably in the next year or two could be undertaken with regard to looking at resistance emergence strategies to reduce the combination therapies with antivirals. Another point of discussion within our group was the need to start studies of the available drugs to determine their impact, and their dose-related impact on some of the important outcomes in H5 disease in South Asia.
Read the entire page →

Key Terms

  • research strategy
  • secondary bacterial
  • virulence factors
  • immune response
  • clinical protocols

  • bacterial pneumonia
  • challenge strains
  • south asia
  • immune modulators
  • virulence defines

  • economic incentives
  • seeing differences
  • includes evaluating
  • organizational dynamics
  • correlate sequence

  • unusually cold
  • useful model
  • clinical trials
  • health education
  • strongly influence

  • rat model
  • common outcome
  • innate immune
  • short period
  • clinical histories

  • patient populations
  • alternative strategies
  • emergence strategies
  • ameliorative strategies
  • international trade


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.